非佐林奈坦治疗绝经期血管舒缩症状的2a期试验
这项为期12周的双盲随机安慰剂对照研究在87名40-65岁有中度/重度血管舒缩症状的绝经期女性中评估NK3R拮抗剂非佐林奈坦90mg每日两次的疗效与安全性。第12周时非佐林奈坦较安慰剂显著降低总VMS评分(-26.5 vs -12.2,P<0.001),并减少中度/重度VMS日均发作频率约5次,从治疗第一天起即有改善,耐受性良好。
要点
- 非佐林奈坦90mg每日两次较安慰剂显著降低第12周总VMS评分。
- 中度/重度VMS严重程度和频率从治疗第一天起即下降。
- 最常见药物相关不良事件为胃肠道紊乱(n=6)。
核心结论
- 非佐林奈坦快速且显著减轻绝经期中度/重度血管舒缩症状,支持其作为有效的非激素治疗选择。
研究设计与样本
- 筛查122人,随机87人,80人(92%)完成研究。
- 受试者为40至65岁、有中度/重度VMS的一般健康绝经期女性,按1:1随机接受非佐林奈坦90mg每日两次或安慰剂。
主要发现
- 第12周非佐林奈坦较安慰剂显著降低总VMS评分(-26.5 vs -12.2,P < 0.001)。
- 非佐林奈坦较安慰剂减少中度/重度VMS日均发作频率约5次。
- 中度/重度VMS的严重程度和频率从治疗第一天起即降低。
- 所有生活质量指标均获得改善。
- 非佐林奈坦耐受性良好,最常见的药物相关不良事件为胃肠道紊乱(n = 6)。
临床怎么用
- 对于有中度/重度血管舒缩症状的绝经期女性,非佐林奈坦可作为非激素治疗选项。
- 治疗中需关注胃肠道不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The thermoregulatory center in the hypothalamus is stimulated by neurokinin 3 receptor (NK3R) activation and inhibited by estrogen-negative feedback. This balance is disrupted in menopause, producing vasomotor symptoms (VMSs). OBJECTIVE: To evaluate safety and efficacy of the NK3R antagonist fezolinetant in menopausal VMSs. DESIGN: Twelve-week, double-blind, randomized, placebo-controlled study. SETTING: Eight Belgian centers from September 2015 to October 2016. PARTICIPANTS: Generally healthy menopausal women aged 40 to 65 years with moderate/severe VMSs. INTERVENTIONS: Subjects were randomized (1:1) to 90 mg of fezolinetant twice daily or placebo for 12 weeks. MAIN OUTCOME MEASURES: Subjects captured VMS severity and frequency using an electronic diary. The primary outcome was change from baseline to week 12 in total VMS score with fezolinetant vs placebo. Secondary outcomes included timing of changes in frequency and severity of moderate/severe VMSs and quality-of-life assessments at weeks 4, 8, and 12. Pharmacodynamic and pharmacokinetic effects were assessed, as were safety and tolerability. RESULTS: Of 122 subjects screened, 87 were randomized and 80 (92%) completed the study. At week 12, fezolinetant significantly reduced total VMS score vs placebo (-26.5 vs -12.2, P < 0.001) and decreased mean frequency of moderate/severe VMSs by five episodes per day vs placebo. Severity and frequency of moderate/severe VMSs were reduced from the first day of treatment. Improvements were achieved in all quality-of-life measures. Fezolinetant was well tolerated. The most common fezolinetant-related adverse event was gastrointestinal disorder (n = 6). CONCLUSIONS: Fezolinetant rapidly and significantly reduced moderate/severe VMSs, supporting its potential as an effective nonhormonal treatment option for menopausal women.
引用
- Depypere H, Timmerman D, Donders G, et al. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. J Clin Endocrinol Metab. 2019. PMID: 31415087. doi:10.1210/jc.2019-00677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。